Sandbox colesevelam: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{SS}} | ||
{{SB}} | {{SB}} WELCHOL tablet | ||
==Overview== | ==Overview== | ||
| Line 20: | Line 20: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Bile Acid Sequestrant]] | [[Catogary:Bile Acid Sequestrant]] | ||
[[Cardiovasular Drugs]] | [[Catogary:Cardiovasular Drugs]] | ||
[[Drugs]] | [[Catogary:Drugs]] | ||
Revision as of 20:58, 20 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Synonyms / Brand Names: WELCHOL tablet
Overview
Colesevelam is a bile acid sequestrant administered orally. It is developed by Genzyme and marketed in the US by Daiichi Sankyo under the brand name Welchol and elsewhere by Genzyme as Cholestagel. In Canada it is marketed by Valeant as Lodalis.
Category
Bile Acid Sequestrant
Prescribing Information
WELCHOL (colesevelam hydrochloride) tablet, film coated
References
Catogary:Bile Acid Sequestrant Catogary:Cardiovasular Drugs Catogary:Drugs